There is a growing consensus that TRPV1, TRPV2, TRPM2, TRPM3, and TRML1 exert anti-tumorigenic properties in glioma, while TRPC1, TRPC6, TRPM7, TRPM8, and TRPML2 promote glioma growth and proliferation. Here, TRPM2 is linked to central nervous system cancer.